109 related articles for article (PubMed ID: 8398824)
1. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.
Brown RD; Joshua DE; Nelson M; Gibson J; Dunn J; MacLennan IC
Br J Haematol; 1993 Jun; 84(2):238-41. PubMed ID: 8398824
[TBL] [Abstract][Full Text] [Related]
2. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
MacLennan IC; Chapman C; Dunn J; Kelly K
Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
[TBL] [Abstract][Full Text] [Related]
3. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.
Brown RD; Joshua DE; Ioannidis RA; Kronenberg H
Aust N Z J Med; 1989 Jun; 19(3):226-32. PubMed ID: 2528340
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome].
Aul C; Germing U; Gattermann N; Söhngen D; Heyll A
Dtsch Med Wochenschr; 1996 Sep; 121(37):1113-8. PubMed ID: 8925725
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
8. Serum deoxythymidine kinase in myelodysplastic syndromes.
Aul C; Gattermann N; Germing U; Winkelmann M; Heyll A; Runde V; Schneider W
Cancer; 1994 Jan; 73(2):322-7. PubMed ID: 8293395
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
10. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma.
Bartl R; Frisch B; Diem H; Mündel M; Nagel D; Lamerz R; Fateh-Moghadam A
Cancer; 1991 Nov; 68(10):2241-50. PubMed ID: 1913461
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
12. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease.
von Euler H; Einarsson R; Olsson U; Lagerstedt AS; Eriksson S
J Vet Intern Med; 2004; 18(5):696-702. PubMed ID: 15515587
[TBL] [Abstract][Full Text] [Related]
13. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
Bladé J; San Miguel JF; Fontanillas M; Alcalá A; Maldonado J; García-Conde J; Conde E; Conzález-Brito G; Moro MJ; Escudero ML; Trujillo J; Pascual A; Rozman C; Estapé J; Montserrat E
J Clin Oncol; 1996 Jul; 14(7):2167-73. PubMed ID: 8683251
[TBL] [Abstract][Full Text] [Related]
14. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Bataille R; Durie BG; Grenier J
Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
[TBL] [Abstract][Full Text] [Related]
16. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
17. Serum thymidine kinase activity in clinically healthy and diseased cats: a potential biomarker for lymphoma.
Taylor SS; Dodkin S; Papasouliotis K; Evans H; Graham PA; Belshaw Z; Westberg S; von Euler HP
J Feline Med Surg; 2013 Feb; 15(2):142-7. PubMed ID: 23076596
[TBL] [Abstract][Full Text] [Related]
18. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
Pavlovsky S; Corrado C; Santarelli MT; Saslavsky J; Cavagnaro F; Palau M; de Tezanos Pinto M; Huberman A; Lein JM
J Clin Oncol; 1988 May; 6(5):769-75. PubMed ID: 3284974
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
